Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience

BACKGROUND: The GEMINI trials established the efficacy of vedolizumab in moderate-to-severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile, suggesting it may be advantageous in older patients at greater risk of treatment-related complications. However, there is a paucit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibraheim, Hajir, Samaan, Mark A., Srinivasan, Ashish, Brain, Oliver, Digby-Bell, Jonathan, Irving, Peter M., Norman, Irena, Jawad, Issrah, Biedermann, Julia, Ibarra, Ana, Kok, Klaartje Bel, Parkes, Gareth, Rimmer, Joanna, Compot, Elisabeta, Parkes, Miles, Segal, Jonathan, Oppong, Philip, Hart, Ailsa, Hayee, Bu’Hussain, Powell, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049246/
https://www.ncbi.nlm.nih.gov/pubmed/32127738
http://dx.doi.org/10.20524/aog.2020.0447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049246/
https://www.ncbi.nlm.nih.gov/pubmed/32127738
http://dx.doi.org/10.20524/aog.2020.0447

Ejemplares similares